Treatment‐related changes in the prostate: past, present and future therapies
Histopathology · 2026-01 · 88 (1) · 40-52
DOI: 10.1111/his.15507 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Histopathology, online erschienen am 12.12.2025. Verfasst von Katrina Collins und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostate. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
A broad spectrum of therapies is available for the management of prostate cancer, ranging from well‐established interventions like radical prostatectomy, androgen deprivation therapy (ADT) and radiation therapy (RT), to emerging modalities such as focal ablative treatments and targeted molecular therapies. These therapies can induce profound histologic alterations in both benign and malignant prostate tissue. Hormonal and radiation therapies are particularly known for their distinctive and often extensive morphologic effects, which have been well documented across needle biopsies, transurethral resection of the prostate (TURP) or enucleation specimens and prostatectomy samples. Novel ablative techniques—including cryotherapy, high‐intensity focused ultrasound (HIFU), photodynamic therapy (PDT) and interstitial laser thermotherapy—are gaining traction, yet the histologic consequences of these newer modalities are still being characterized. These treatment‐induced changes can obscure residual carcinoma, complicate tumour grading and staging and sometimes render traditional parameters such as Gleason scoring unreliable. As therapies evolve, pathologists must remain informed about the spectrum of post‐treatment changes to accurately interpret prostate specimens. Diagnostic accuracy hinges not only on recognizing these morphologic effects but also on integrating clinical history, particularly when treatment details are not readily available. This review provides an overview of current and investigational prostate cancer therapies, their histologic impact and practical guidance for post‐treatment evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
- Department of Pathology and Laboratory Medicine, Department of Surgery (Urology), Brown University Warren Alpert Medical School, The Legorreta Cancer Center at Brown University, and Brown University Health, Providence,…
ORCID-Profile: Katrina Collins, Liang Cheng
Zitieren
APA
Collins, K., & Cheng, L. (2026). Treatment‐related changes in the prostate: past, present and future therapies. Histopathology, 88(1), 40-52. https://doi.org/10.1111/his.15507
Vancouver
Collins K, Cheng L. Treatment‐related changes in the prostate: past, present and future therapies. Histopathology. 2026;88(1):40-52. doi:10.1111/his.15507
BibTeX
@article{Collins2026,
author = {Collins, Katrina and Cheng, Liang},
title = {Treatment‐related changes in the prostate: past, present and future therapies},
journal = {Histopathology},
year = {2026},
volume = {88},
number = {1},
pages = {40--52},
doi = {10.1111/his.15507}
}
EUVIMED